- Home
- LXEH vs SNGX Comparison
LXEH vs SNGX Comparison
Compare LXEH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- SNGX
- Stock Information
- Founded
- LXEH 2001
- SNGX 1987
- Country
- LXEH China
- SNGX United States
- Employees
- LXEH N/A
- SNGX N/A
- Industry
- LXEH Other Consumer Services
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- SNGX Health Care
- Exchange
- LXEH Nasdaq
- SNGX Nasdaq
- Market Cap
- LXEH 6.2M
- SNGX 7.4M
- IPO Year
- LXEH 2020
- SNGX 1987
- Fundamental
- Price
- LXEH $9.38
- SNGX $2.43
- Analyst Decision
- LXEH
- SNGX
- Analyst Count
- LXEH 0
- SNGX 0
- Target Price
- LXEH N/A
- SNGX N/A
- AVG Volume (30 Days)
- LXEH 58.4K
- SNGX 31.0K
- Earning Date
- LXEH 03-15-2025
- SNGX 03-14-2025
- Dividend Yield
- LXEH N/A
- SNGX N/A
- EPS Growth
- LXEH N/A
- SNGX N/A
- EPS
- LXEH N/A
- SNGX N/A
- Revenue
- LXEH $5,628,870.00
- SNGX $364,183.00
- Revenue This Year
- LXEH N/A
- SNGX N/A
- Revenue Next Year
- LXEH N/A
- SNGX $76.64
- P/E Ratio
- LXEH N/A
- SNGX N/A
- Revenue Growth
- LXEH N/A
- SNGX N/A
- 52 Week Low
- LXEH $1.95
- SNGX $1.83
- 52 Week High
- LXEH $65.06
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- LXEH 69.93
- SNGX 46.06
- Support Level
- LXEH $8.22
- SNGX $2.35
- Resistance Level
- LXEH $10.25
- SNGX $2.47
- Average True Range (ATR)
- LXEH 0.76
- SNGX 0.13
- MACD
- LXEH 0.14
- SNGX 0.04
- Stochastic Oscillator
- LXEH 82.32
- SNGX 61.36
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).